REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced a late-breaking oral presentation of briquilimab data from the Phase 1b/2a BEACON in CSU study at the 2025 AAD Annual Meeting, being held March 7 – 11, 2025, in Orlando, FL. The presentation will consist of data from patients included in the Company’s January 8th, 2025, disclosure of preliminary data from the BEACON study.
Details of the presentation are as follows:
Abstract Title: Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study
Abstract Number: S040
Session Title: Late Breaking Research: Session 2
Session Type: Oral Abstract Session
Presentation Date / Time: Saturday, March 8, 2025; 1 p.m. PST
About Jasper
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. …
